arrow
L

Lorenza Landi

university of verona
H指数:34
被引数:4,402

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study

PD-L1 ≥ 50% 非小细胞肺癌中cemiplimab单药或联合短程化疗的超进展:一项生物标志物指导的多中心国际II期试验—HYPERBOLIC研究

2026-09-010
PRE
First-line treatment in EGFR-mutated non-small cell lung cancer: brief report of an individual patient data comparison of phase 3 clinical trials

EGFR突变非小细胞肺癌的一线治疗:一项基于个体患者数据的Ⅲ期临床 trial 比较的简报

2025-11-190
OAAI
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

长期接受帕博利珠单抗单药治疗的患者中,具有晚期非小细胞肺癌、PD-L1表达≥50%且体力状况较差者的长期结局:基于Transformer的AI用于表征预后复杂性

2025-10-160
OAAI
TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma

TP53共突变增加了EGFR突变的Ⅰ期肺腺癌的复发风险。

2025-07-100
PRE
ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC

ETOP 25-23 ADOPT-lung:一项国际、多中心、开放标签的随机III期试验,旨在评估在术前新辅助化疗联合durvalumab的基础上,为可切除的IIB-IIIB(N2)期非小细胞肺癌(NSCLC)患者添加辅助durvalumab治疗的获益。

2025-06-230
OA
Spatial transcriptomics highlights B cells as key contributors to a complete and durable response to chemo-immunotherapy in a patient with resectable NSCLC

空间转录组学凸显B细胞作为对可切除非小细胞肺癌患者化疗免疫治疗产生完全且持久应答的关键贡献者。

2025-05-110
OA
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials
2023-12-0121
OAAI
The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world

里贾纳·埃琳娜国家癌症研究所的分子肿瘤委员会: 从应计到现实世界的治疗

2023-10-164
OAAI
ALBA project: Prognostic impact of laterality in small cell lung cancer

ALBA项目: 偏侧性对小细胞肺癌预后的影响

2023-10-010
OAAI
Pretreated EGFRdel19/BRAFV600E Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case Report

经预处理的EGFRdel19/BRAFV600E患有软脑膜疾病的肺腺癌,在奥希替尼,达拉非尼和曲美替尼的治疗中实现了长期的疾病控制: 一例病例报告

2023-08-012
OA
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

卡培他滨辅助治疗新辅助治疗后有残留病灶的三阴性乳腺癌患者: 来自CaRe的真实世界证据,一项多中心观察性研究

2023-05-165
OAAI
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

KRASG12C抑制剂在晚期NSCLC中的疗效和作用

2023-04-1765
OA
Molecular determinants of KRAS p.G12C inhibitor efficacy in advanced NSCLC
2023-04-040
PRE
Combi-TED: a new trial testing Tedopi® with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line
2023-03-223
PRE
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting

Paner研究: 一项来自真实世界环境的HER2-positive晚期乳腺癌患者的多中心观察性研究的20年治疗结果分析

2021-11-296
OAAI